FK 866 hydrochloride
Cat. No. 4808
Chemical Name: 2-(E)-N-[4-(1-Benzoyl-4-piperidinyl
Biological ActivityNon-competitive and potent inhibitor of NAMPT (nicotinamide phosphoribosyltransferase, visfatin, PBEF1) (Ki = 0.3 nM); inhibits NAD biosynthesis. Induces delayed cell death by apoptosis in HepG2 human liver carcinoma cells (IC50 ~1 nM). Induces apoptosis in four different neuroblastoma cell lines; also induces autophagy in SH-SY5Y cells. Potentiates the cytotoxic effects induced by etoposide (Cat. No. 1226) and cisplatin (Cat. No. 2251).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Travelli et al (2011) Reciprocal potentiation of the antitumoral activities of FK866, an inhibitor of nicotinamide phosphoribosyltransferase, and etoposide or cisplatin in neuroblastoma cells. J.Pharmacol.Exp.Ther. 338 829. PMID: 21685314.
Galli et al (2008) Synthesis and biological evaluation of isosteric analogues of FK866, an inhibitor of NAD salvage. ChemMedChem 3 771. PMID: 18247435.
Hasmann et al (2003) FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63 7436. PMID: 14612543.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses FK 866 hydrochloride from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: FK 866 hydrochloride, supplier, FK866, hydrochloride, Nicotinamide, phosphoribosyltransferase, NMPRTase, inhibitors, inhibits, autophagy, apoptosis, NAD, NAMPT, visfatin, PBEF, Tocris Bioscience, NAMPT Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent cholesteryl ester transfer protein (CETP) inhibitorPerhexiline maleate
Carnitine palmitoyltransferase 1 and 2 (CPT1/2) inhibitorMS 023 dihydrochloride
Potent and selective type I PRMT inhibitor
April 1 - 5, 2017
Washington, D.C., USA